【简介】博士后招聘网整理分享“美国莫菲特癌症中心2021年招聘博士后职位（肿瘤免疫学）”，浏览查询更多博士后招聘计划请访问博士后招聘网。

美国莫菲特癌症中心2021年招聘博士后职位（肿瘤免疫学）

H. Lee Moffitt Cancer Center & Research Institute

At Moffitt Cancer Center, we come face-to-face with cancer every day, but we also see courage. And it inspires us to be the safest and best place for cancer care – to bring greater hope to every patient we serve. It’s why we’ve been continually named One of the Top Places to Work in the Tampa Bay Area. As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt employs some of the best and brightest minds from around the world. Moffitt is the leading cancer hospital in both Florida and the Southeast and has been nationally ranked by U.S. News & World Report since 1999. Because working at Moffitt is both a career and a mission: to contribute to the prevention and cure of cancer. Join a dedicated, diverse and inclusive team of over 7,000 to be a part of the Courageous future we envision.

Summary

Postdoctoral Scholar – Tumor Immunology

The Haura lab has an opening for a postdoctoral scholar in tumor immunology and adoptive cell therapy research. Moffitt’s trajectory is to become a worldwide leader in cell therapy for cancer. Our lab uses an interdisciplinary approach spanning immune biology and proteogenomics to functionally characterize responses to immune therapy. We are looking for a highly motivated and independent postdoctoral research fellow who is interested in working on a project related to tumor neoantigens that predict response to tumor infiltrating lymphocytes (TIL) trial therapy in lung cancer patients, recently published in Nature Medicine (https://www.nature.com/articles/s41591-021-01462-y)

Position Highlights:

The candidate will have immediate access to rich array of patient samples including resected tumors and tumor cell suspensions, and apheresis products and will join a productive, energetic team of immunologists, bioinformaticians, clinicians, surgeons, and protein researchers within our group.

The Ideal Candidate:

Successful candidates will have a publication track record demonstrating a strong background in tumor immunology and/or immune-therapy; with an interest in translational research. Prior experience is required with some of the following techniques: high-throughput screening, lymphocyte cell culture (T cells and dendritic cells), ELISA/ELISpot assay, nucleic acids/protein extraction, flow cytometry (FACS). Expertise in molecular biology (cloning, plasmid purification) and adoptive cell therapy is highly preferred. Candidates with experience in validating neoantigens in model systems will be given priority.

Responsibilities:

This individual will design, conduct and interpret correlative experiments using human samples from accruing immunotherapy clinical trials, in particular a trial using adoptive cell transfer of tumor infiltrating lymphocytes (TIL). This individual will identify and validate predicted neoantigens from lung cancer immunotherapy trials using established and novel functional assays.

Credentials and Qualifications:

M.D. or PhD in Molecular Biology, Immunology, Biochemistry, or relevant field.

Interested applicants should send their current CV with recent publications and contact information for three references to Dr. Eric Haura at Eric.Haura@moffitt.org,

Moffitt Cancer Center is a premier cancer research institution in the United States. Built in an attractive location, it is the only NCI-designated cancer center in Florida and one of the top institutions in systems medicine and personalized cancer therapy. Moffitt features a number of high-quality core facilities equipped with state-of-the-art instrumentation and a cluster of expertise particularly in adoptive cell therapies.

更多最新博士后招收信息请关注博士后招聘网微信公众号（ID：boshihoujob）

请您在邮件申请时在标题注明信息来自：博士后招聘网-boshihoujob.com，电话咨询时说明从博士后招聘网(www.boshihoujob.com)看到的博士后招聘信息。

声明：凡本网注明“来源：XXX”的文/图等稿件，本网转载出于传递更多信息及方便产业探讨之目的，并不意味着本站赞同其观点或证实其内容的真实性，文章内容仅供参考。如其他媒体、网站或个人从本网站转载使用，须保留本网站注明的“来源”，并自负版权等法律责任。作者如果不希望被转载或者联系转载等事宜，请与我们联系。邮箱：boshihoujob@163.com。